Characterizing ovarian pathology: Refining the performance of ultrasonography

International Journal of Gynecological Cancer

Volumn 22, Issue SUPPL. 1, 2012, Pages

  Timmerman, Dirk ^a   Bourne, Tom ^a,b   De Rijdt, Sylvie ^a   Kaijser, Jeroen ^a   Van Calster, Ben ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b QUEEN CHARLOTTE S AND CHELSEA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SIZE; CANCER SURGERY; CONFERENCE PAPER; FEMALE; FOLLOW UP; HUMAN; LOGISTIC REGRESSION ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; TRANSVAGINAL ECHOGRAPHY;

ADNEXAL DISEASES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LOGISTIC MODELS; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84863714149     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318251c9df     Document Type: Conference Paper

References (16)

1. Crayford TJB, Campbell S, Bourne TH et al. Benign ovarian cysts and ovarian cancer: a cohort study with implications for screening. Lancet. 2000;355:1060-1063. (Pubitemid 30162809)
2. Prorok PC, Andriole GL, Bresalier RS, et al; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21:273S-309S.
3. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10:327-340.
4. Buys SS, Partridge E, Black A, et al; PLCO Project Team. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305: 2295-2303.
5. Bourne TH, Campbell S, Reynolds KM, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ. 1993;306:1025-1029. (Pubitemid 23105959)
6. Campbell S, Bhan V, Royston P, et al. Transabdominal ultrasound screening for early ovarian cancer. BMJ. 1989;299:1363-1367. (Pubitemid 20005300)
7. Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97:922-929. (Pubitemid 20340625)
8. Valentin L, Hagen B, Tingulstad S, et al. Comparison of 'pattern recognition' and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation. Ultrasound Obstet Gynecol. 2001;18:357-365. (Pubitemid 32947204)
9. Aslam N, Banerjee S, Carr JV, et al. Prospective evaluation of logistic regression models for the diagnosis of ovarian cancer. Obstet Gynecol. 2000;96:75-80. (Pubitemid 30336284)
10. Timmerman D, Testa AC, Bourne T, et al. Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol. 2005;23:8794-8801. (Pubitemid 46211525)
11. Timmerman D, Valentin L, Bourne TH, et al. Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol. 2000;16:500-505. (Pubitemid 32158133)
12. Timmerman D, Van Calster B, Testa AC, et al. Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group. Ultrasound Obstet Gynecol. 2010;36:226-234.
13. Timmerman D, Testa AC, Bourne T, et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol. 2008;31:681-690.
14. Timmerman D, Ameye L, Fischerova D, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ. 2010;341:c6839.
15. RCOG guideline: management of suspected ovarian masses in premenopausal women. December 2011. (Green top 62). Available at: http://www.rcog.org.uk. Accessed December 2, 2011.
16. Van Calster B, Valentin L, Van Holsbeke C, et al. Polytomous diagnosis of ovarian tumors as benign, borderline, primary invasive or metastatic: development and validation of standard and kernel-based risk prediction models. BMC Med Res Methodol. 2010;10:96.